

Supplemental Table 1. Clinical characteristics of RMD participants taking mycophenolate stratified by withholding mycophenolate peri-vaccination

	Continued mycophenolate (n=171)	Held mycophenolate (n=24)	p-value
Age, median (IQR)	45.7 (37.3, 58.4)	51.1 (39.5, 58.4)	0.5
Male sex, no. (%)	18 (10.5%)	2 (8.3%)	>0.99
Days from D2 to testing, median (IQR)	29.0 (28.0, 34.0)	32.0 (28.0, 35.0)	0.29
Non-white, no. (%)	27 (15.8%)	1 (4.2%)	0.21
Diagnosis, no. (%)			0.001
Inflammatory arthritis*	5 (2.9%)	2 (8%)	
Systemic lupus erythematosus	56 (32.7%)	6 (25%)	
Sjögren's syndrome	3 (1.8%)	1 (4%)	
Myositis	24 (14.0%)	5 (21%)	
Systemic sclerosis	5 (2.9%)	4 (17%)	
Vasculitis†	6 (3.5%)	0 (0%)	
Other‡	35 (20.5%)	2 (8%)	
Overlap connective tissue disease§	38 (22.2%)	4 (17%)	
Vaccine, no. (%)			0.09
Pfizer	91 (53.2%)	13 (54.2%)	
Moderna	75 (43.9%)	8 (33.3%)	
J&J	5 (2.9%)	5 (2.9%)	
Therapy included in regimen, no. (%)			
Azathioprine	3 (1.8%)	1 (4.2%)	0.41
Hydroxychloroquine	79 (46.2%)	5 (20.8%)	0.03
Leflunomide	4 (2.3%)	0 (0.0%)	>0.99
Methotrexate	3 (1.8%)	0 (0.0%)	>0.99
Tacrolimus	11 (6.4%)	0 (0.0%)	0.37
Abatacept	0 (0.0%)	3 (12.5%)	0.002

Belimumab	18 (10.5%)	1 (4.2%)	0.48
Interleukin-17 inhibitor	1 (0.6%)	0 (0.0%)	>0.99
Rituximab	16 (9.4%)	2 (8.3%)	>0.99
TNF inhibitor	6 (3.5%)	1 (4.2%)	>0.99
Tofacitinib	0 (0.0%)	1 (4.2%)	0.12
Glucocorticoid^{**}	76 (44.4%)	9 (37.5%)	0.66
Immunomodulatory 	18 (10.5%)	1 (4.2%)	0.48
Combination therapy[¶]	100 (58.5%)	13 (54.2%)	0.83

* Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, or inflammatory bowel disease associated arthritis

† Polyarteritis nodosa, Behcet's syndrome, polymyalgia rheumatica, temporal arteritis, eosinophilic granulomatosis polyangiitis, granulomatous polyangiitis, Henoch-Schonlein purpura, microscopic polyangiitis, or Takayasu arteritis

‡ Includes Adult Onset Still's disease, connective tissue related interstitial lung disease, autoimmune hepatitis

§ Denotes a combination of two or more of the rheumatic conditions

^{||} TNF inhibitors include adalimumab, certolizumab, etanercept, golimumab, and infliximab. Corticosteroid includes prednisone and prednisone equivalents. Immunomodulatory includes intravenous immunoglobulin (IVIg) and subcutaneous Immunoglobulin (SCIg).

^{**} Glucocorticoid includes prednisone and prednisone equivalents.

[¶] Denotes a combination of conventional DMARD, biologic, corticosteroid, or immunomodulatory therapy

